Polymarket · NPR Technology
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Compiled by KHAO Editorial — aggregated from 1 source + 1 reference discovered via search. See llms.txt for citation guidance.
◌ Single Source
Kalshi and Polymarket say allowing people to bet on the outcomes of clinical trials and FDA drug approvals provides valuable information about drug development.
Key facts
- As a soon-to-be seventh grader, Joshua Pederson's son is not exactly brimming with enthusiasm when he talks about the upcoming school year
- The thing I'm looking forward to most in seventh grade is lunch, and the thing I'm looking forward to least is everything else," said the 12-year-old
- So Pederson entered his son into a clinical trial for a novel treatment
- David Tsai, who runs clinical trials at a biotech company in the San Francisco Bay Area, started an online petition pushing for such betting to be banned, making the case that betting on drug trials
Summary
As a soon-to-be seventh grader, Joshua Pederson's son is not exactly brimming with enthusiasm when he talks about the upcoming school year. "The thing I'm looking forward to most in seventh grade is lunch, and the thing I'm looking forward to least is everything else," said the 12-year-old. Art is his passion, but he doesn't take classes. "I like drawing scary stuff and robots," he said.